pp 1–8 | Cite as

8-Foot-Up-and-Go Test is Associated with Hospitalizations and Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Pilot Study

  • Baruch VainshelboimEmail author
  • Mordechai Reuven Kramer
  • Jonathan Myers
  • Avraham Unterman
  • Shimon Izhakian
  • Jose Oliveira



To assess the prognostic value of the 8-foot-up-and-go test (8-FUGT) in pilot cohort of patients with idiopathic pulmonary fibrosis (IPF).


Thirty-four patients with IPF (68 ± 8 years) underwent 8-FUGT at baseline and were followed for up to 40 months. Receiver operating characteristics and age-adjusted Cox hazard ratios (HR) were analyzed for 8-FUGT, hospitalizations, and mortality. Correlation coefficients were determined between 8-FUGT and other exercise tests.


8-FUGT ≥ 6.9 s was found to be associated with hospitalization (sensitivity = 77%, specificity = 76%, p = 0.03) and mortality (sensitivity = 91%, specificity = 70% p = 0.008) in patients with IPF. Categorical models demonstrated that 8-FUGT ≥ 6.9 s was associated with 14.1- (p < 0.001) and 55.4-fold (p = 0.001) increased risks for hospitalization and mortality, respectively. In continuous models, for every 1-s slower performance in the 8-FUGT there were 54% [HR = 1.54, 95% CI (1.11–2.15) p = 0.01] increased risk for hospitalization and 94% [HR = 1.94, 95% CI (1.26–2.99) p = 0.003] increased risk for mortality. 8-FUGT was inversely related to 6-min walk distance (r = − 0.61), peak oxygen consumption (r = − 0.58), and peak work rate (r = − 0.72), all p < 0.001.


The 8-FUGT was strongly associated with hospitalizations and mortality in patients with IPF, as well as correlated with established prognostic markers. These novel findings suggest a prognostic value of the 8-FUGT for risk stratification, referral to pulmonary rehabilitation, and considering listing for lung transplantation. 8-FUGT is an inexpensive and practical tool that has prospective for implementation in clinical and research settings in IPF. Future prospective studies should evaluate the effect of changes in 8-FUGT on clinical outcomes.

Trial registration



Functional capacity Survival Prognostic predictors Risk stratification Clinical outcomes 


Author Contributions

BV was responsible for study design and conception, data collection, results interpretation, statistical analysis, drafting, writing, and submitting the manuscript. MRK supervising physician of the study was responsible for study design and conception, results interpretation, drafting the article, and revising it critically for important intellectual content. JM was involved in results interpretation, statistical analysis, drafting the article, and revising it critically for important intellectual content. AU and SI participated in results interpretation, statistical analysis, drafting the article, and revising it critically for important intellectual content. JO was involved in study design and conception, results interpretation, statistical analysis, drafting the article, and revising it critically for important intellectual content. All authors have read and approved the manuscript.


No funding was received for this study.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK (2007) Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 176(3):277–284. CrossRefPubMedGoogle Scholar
  3. 3.
    Meltzer EB, Noble PW (2008) Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 3:8. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Swigris JJ, Brown KK, Make BJ, Wamboldt FS (2008) Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation. Respir Med 102(12):1675–1680. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK (2005) Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 60(7):588–594. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    American Thoracic Society (ATS), and the European Respiratory Society (ERS) (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161 (2 Pt 1):646–664Google Scholar
  7. 7.
    Kistler KD, Nalysnyk L, Rotella P, Esser D (2014) Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med 14(1):139. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, Rogliani P (2012) Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 40(1):101–109. CrossRefPubMedGoogle Scholar
  9. 9.
    Fernandez Perez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, Yi ES, Ryu JH (2010) Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 137(1):129–137. CrossRefPubMedGoogle Scholar
  10. 10.
    King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM (2001) Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164(7):1171–1181CrossRefGoogle Scholar
  11. 11.
    Ley B, Collard HR, King TE Jr (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183(4):431–440. CrossRefPubMedGoogle Scholar
  12. 12.
    du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr (2014) 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 43(5):1421–1429. CrossRefPubMedGoogle Scholar
  13. 13.
    Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S (2009) Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 103(1):117–123. CrossRefPubMedGoogle Scholar
  14. 14.
    Lederer DJ, Arcasoy SM, Wilt JS, D’Ovidio F, Sonett JR, Kawut SM (2006) Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174(6):659–664. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Tuppin MP, Paratz JD, Chang AT, Seale HE, Walsh JR, Kermeeen FD, McNeil KD, Hopkins PM (2008) Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation. J Heart Lung Transplant 27(7):729–734. CrossRefPubMedGoogle Scholar
  16. 16.
    Kawut SM, O’Shea MK, Bartels MN, Wilt JS, Sonett JR, Arcasoy SM (2005) Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med 99(11):1431–1439. CrossRefPubMedGoogle Scholar
  17. 17.
    Singh SJ, Puhan MA, Andrianopoulos V, Hernandes NA, Mitchell KE, Hill CJ, Lee AL, Camillo CA, Troosters T, Spruit MA, Carlin BW, Wanger J, Pepin V, Saey D, Pitta F, Kaminsky DA, McCormack MC, MacIntyre N, Culver BH, Sciurba FC, Revill SM, Delafosse V, Holland AE (2014) An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J 44(6):1447–1478. CrossRefPubMedGoogle Scholar
  18. 18.
    ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 (1):111–117CrossRefGoogle Scholar
  19. 19.
    American College of Sports Medicine (2014) ACSM’s guidelines for exercise testing and prescription, 9th edn. Wolters Kluwer/Lippincott Williams & Wilkins Health, PhiladelphiaGoogle Scholar
  20. 20.
    Rikli RE, Jones CJ (2001) The senior fitness test manual. Human Kinetics, Champaign, pp. 111–151Google Scholar
  21. 21.
    Rikli RE, Jones CJ (1999) Development and validation of a functional fitness test for community-residing older adults. Aging Phys Act 7:129–161CrossRefGoogle Scholar
  22. 22.
    Rolenz E, Reneker JC (2016) Validity of the 8-foot up and go, timed up and go, and activities-specific balance confidence scale in older adults with and without cognitive impairment. J Rehabil Res Dev 53(4):511–518. CrossRefPubMedGoogle Scholar
  23. 23.
    Rose DJ, Lucchese JC, N (2002) Predicting the probability of falls in community-residing older adults using the 8-foot up-and-go: a new measure of functional mobility. J Aging Phys Act 10:466–475CrossRefGoogle Scholar
  24. 24.
    Vainshelboim B, Oliveira J, Fox BD, Soreck Y, Fruchter O, Kramer MR (2015) Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung 193(3):345–354. CrossRefPubMedGoogle Scholar
  25. 25.
    Vainshelboim B, Oliveira J, Yehoshua L, Weiss I, Fox BD, Fruchter O, Kramer MR (2014) Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration 88(5):378–388. CrossRefPubMedGoogle Scholar
  26. 26.
    Vainshelboim B, Oliveira J, Fox BD, Kramer MR (2016) The prognostic role of ventilatory inefficiency and exercise capacity in idiopathic pulmonary fibrosis. Respir Care. CrossRefPubMedGoogle Scholar
  27. 27.
    Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26(4):720–735. CrossRefPubMedGoogle Scholar
  28. 28.
    Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G (2005) Standardisation of the measurement of lung volumes. Eur Respir J 26(3):511–522. CrossRefPubMedGoogle Scholar
  29. 29.
    Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC (1993) Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 16:5–40CrossRefGoogle Scholar
  30. 30.
    ATS/ACCP statement on cardiopulmonary exercise testing. (2003) Am J Respir Crit Care Med 167 (2):211–277.
  31. 31.
    Fletcher GF, Ades PA, Kligfield P, Arena R, Balady GJ, Bittner VA, Coke LA, Fleg JL, Forman DE, Gerber TC, Gulati M, Madan K, Rhodes J, Thompson PD, Williams MA, American Heart Association Exercise CR, Prevention Committee of the Council on Clinical Cardiology CoNPA, Metabolism CoC, Stroke N, Council on E, Prevention (2013) Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation 128(8):873–934. CrossRefPubMedGoogle Scholar
  32. 32.
    Fell CD, Liu LX, Motika C, Kazerooni EA, Gross BH, Travis WD, Colby TV, Murray S, Toews GB, Martinez FJ, Flaherty KR (2009) The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179(5):402–407. CrossRefPubMedGoogle Scholar
  33. 33.
    Triantafillidou C, Manali E, Lyberopoulos P, Kolilekas L, Kagouridis K, Gyftopoulos S, Vougas K, Kotanidou A, Alchanatis M, Karakatsani A, Papiris SA (2013) The role of cardiopulmonary exercise test in IPF prognosis. Pulm Med 2013:514817. CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Miki K, Maekura R, Hiraga T, Okuda Y, Okamoto T, Hirotani A, Ogura T (2003) Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis. Respir Med 97(5):482–490CrossRefGoogle Scholar
  35. 35.
    Wallaert B, Guetta A, Wemeau-Stervinou L, Terce G, Valette M, Neviere R, Aguilaniu B (2011) [Prognostic value of clinical exercise testing in idiopathic pulmonary fibrosis]. Rev Mal Respir 28(3):290–296. CrossRefPubMedGoogle Scholar
  36. 36.
    Nakayama M, Bando M, Araki K, Sekine T, Kurosaki F, Sawata T, Nakazawa S, Mato N, Yamasawa H, Sugiyama Y (2015) Physical activity in patients with idiopathic pulmonary fibrosis. Respirology. CrossRefPubMedGoogle Scholar
  37. 37.
    Kozu R, Jenkins S, Senjyu H (2011) Effect of disability level on response to pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 16(8):1196–1202. CrossRefPubMedGoogle Scholar
  38. 38.
    Layton AM, Armstrong HF, Kim HP, Meza KS, D’Ovidio F, Arcasoy SM (2017) Cardiopulmonary exercise factors predict survival in patients with advanced interstitial lung disease referred for lung transplantation. Respir Med 126:59–67. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Master of Cancer Care Program, School of Health SciencesSaint Francis UniversityLorettoUSA
  2. 2.Pulmonary InstituteRabin Medical Center, Beilinson HospitalPetach TikvaIsrael
  3. 3.Research Center in Physical Activity, Health and Leisure (CIAFEL), Faculty of SportUniversity of PortoPortoPortugal
  4. 4.Cardiology DivisionVeterans Affairs Palo Alto Health Care System/Stanford UniversityPalo AltoUSA
  5. 5.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations